All In Biotech

Free tool

FAERS Monitor: Tivdak

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761208 or its brand name (Tivdak, Tisotumab Vedotin-Tftv). Reports on generic versions are filed under their own applications.

Reports

971

Serious

609

63% of reports

Hospitalization

237

Death reported

81

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • malignant neoplasm progression80
  • neuropathy peripheral79
  • nausea66
  • dry eye55
  • conjunctivitis52
  • rash47
  • off label use42
  • death40
  • diarrhoea40
  • anaemia35
  • fatigue34
  • eye disorder31
  • epistaxis29
  • vomiting26
  • weight decreased26

Reports by year received

View as table
YearReports
20196
202014
202124
2022172
2023186
2024182
2025232
2026155

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,188 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
conjunctivitisSignal5260.946.72,998
dry eyeSignal5523.918.51,185
eye disorderSignal3120.414.5554
neuropathy peripheralSignal7918.014.61,256
malignant neoplasm progressionSignal8016.913.71,188
epistaxisSignal298.45.9182
anaemiaSignal354.02.976
rashSignal472.31.835
weight decreasedSignal262.01.413
nausea661.81.424
diarrhoea401.31.03
vomiting261.20.81
off label use421.00.80
death401.00.70
fatigue340.90.70

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.